Philippe Drouet, Biotheryx CEO
April 5, 2023 10:59 AM EDTUpdated 11:11 AM
Deals
R&D

In­cyte links arms with tiny Bio­th­eryx for pro­tein de­grad­er deal, tar­get­ing can­cer

Paul Schloesser

Associate Editor

In­cyte is jump­ing in on Bio­th­eryx’s plat­form, look­ing for po­ten­tial pro­tein de­graders for a new, undis­closed on­col­o­gy tar­get.

The deal,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times